Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil

Chemotherapy

Volumn 51, Issue 2-3, 2005, Pages 132-141

  Rosenthal, Mark A ^a   Gibbs, Peter ^a   Brown, Tracey J ^b   Wong, Shirley ^a   Uren, Shannon ^a   Ellis, Andrew ^c   Li, Lingli ^d   Heldin, Paraskevi ^d   Fox, Richard M ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

5 Fluorouracil; Chemotherapy; Doxorubicin; Drug delivery; Hyaluronan; Toxicity

Indexed keywords

DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; HYALURONIC ACID;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERTENSION; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; HYALURONIC ACID; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS;

EID: 22144488513     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085621     Document Type: Article

References (37)

1. Torchilin VP: Drug targeting. Eur J Pharm Sci 2000;11:S81-S91.
2. Myers CE, Chabner BA: Anthracylcines; in Chabner BA, Collins JM (eds): Cancer Chemotherapy - Principles and Practice. Philadelphia, Lippincott, 1990, pp 356-381.
3. Barutca S, Ceyhan C, Meydan N, Ozturk B, Tekten T, Onbasili A, Kadikoylu G, Bolaman Z: A new perspective on cardiotoxicity of 5-fluorouracil. A novel research tool 'cardiac ultrasonic integrated backscatter analysis' indicates transient, subclinical myocardial dysfunction due to high-dose leucovorin and infusional 5-fluorouracil regimen. Chemotherapy 2004;50:113-118.
4. Maeda H, Matsumura Y: Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989;6:193-210.
5. Maeda H, Seymour LW, Miyamoto Y: Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992;3:351-362.
6. Maeda H, Sawa T, Konno T: Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001;74:47-61.
7. Fraser JRE, Laurent TC: Hyaluronan; in Comper WD (ed): Extracellular Matrix. 2. Molecular Components and Intercellular Interactions. Amsterdam, Harwood Academic Publishers, 1996, pp 141-199.
8. Brown TJ, Hatherell JC, Falzon JL, Brownlee GR, Pho MH, Savani RC, Fraser JRE, Fox RM, Wilson JC: Hyaluronan targeting of antimetabolite anticancer drugs to human breast tumor xenografts. Cancer Chemother Pharmacol, submitted.
9. Wang C, Thor AD, Moore DH, Zhao Y, Kerschmann R, Stern R, Watson PH, Turley EA: The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with over-expression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 1998;4:567-576.
10. Lee JH, Kang YS, Kim BG, Park SY, Lee ED, Lee KH, Park KB: Expression of the CD44 adhesion molecule in primary and metastatic gynecologic malignancies and their cell lines. Int J Gynecol Cancer 1995;5:193-199.
11. Bhatavdekar JM, Patel DD, Chikhlikar PR, Trivedi TI, Gosalia NM, Ghosh N, Shah NG, Vora HH, Suthar TP: Overexpression of CD44: A useful independent predictor of prognosis in patients with colorectal carcinomas. Ann Surg Oncol 1998;5:495-501.
12. Culty M, Nguyen HA, Underhill CB: The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol 1992;116:1055-1062.
13. Culty M, Shizari M, Thompson EW, Underhill CB: Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: Correlation with invasive potential. J Cell Physiol 1994;160:275-286.
14. Klaus GG, Janossy G, Humphrey JH: The immunologjcal properties of haptens coupled to thymus-independent carrier molecules. 3. The role of the immunogenicity and mitogenicity of the carrier in the induction of primary IgM anti-hapten responses. Eur J Immunol 1975;5:105-111.
15. Larsen NE, Balazs EA: Drug delivery systems using hyaluronan and its derivatives. Adv Drug Deliv Rev 1991;7:279-293.
16. Akima K, Ho H, Iwata Y, Matsuo K, Watari N, Yanagi M, Hagi H, Oshima K, Yagita A, Atomi Y, Tatekawa I: Evaluation of antitumor activities of hyaluronate binding antitumor drugs: Synthesis, characterization and antitumor activity. J Drug Target 1996;4:1-8.
17. Luo Y, Prestwich GD: Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem 1999;10:755-763.
18. 13C NMR study. Proc Natl Acad Sci USA 1999;96:4850-4855.
19. Scott JE, Cummings C, Brass AY, Chen Y: Secondary and tertiary structures of hyaluronan in aqueous solution, investigated by rotary shadowing-electron microscopy and computer stimulation. Biochem J 1991;274:699-705.
20. Wilson JC, Brown TJ, Brownlee GR, Hatherell EM, Falzon JL, Fraser JRE: A NMR study of the nature of the interaction of hyaluronan with cytotoxic drugs. Hyaluronan conference, Wrexham, 2000, abstract 20.
21. Brown TJ, Hatherell JC, Falzon JL, Allan P, Pho MH, Fox RM, Fraser JRE, Wilson JC, Savani RC, Brownlee GR: Hyaluronan functions as a chemotransport vehicle in the treatment of human breast cancer xenografts. Cancer Chemother Pharmacol, submitted.
22. Engstrom-Laurent A, Hallgren R: Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients. Relationship to synovitis mass and morning stiffness. Arthritis Rheum 1987;12:1333-1338.
23. Lebel L, Gabrielsson J, Laurent TC, Gerdin B: Kinetics of circulating hyaluronan in humans. Eur J Clin Invest 1994;24:621-626.
24. Fraser JR, Laurent TC, Engstrom-Laurent A, Laurent UG: Elimination of hyaluronic acid from the blood stream in the human. Clin Exp Pharmacol Physiol 1984;111:17-25.
25. 11C]Hyaluronan uptake with positron emission tomography in liver disease. Eur J Clin Invest 2000;7:600-607.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
27. Tengblad A: Affinity chromatography on immobilized hyaluronate and its application to the isolation of hyaluronate binding proteins from cartilage. Biochim Biophys Acta 1979;578:281-289.
28. Jacobson A, Rahmanian M, Rubin K, Heldin P: Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer 2002;102:212-219.
29. Coradini D, Pellizzaro C, Miglierini G, Daidone MG, Perbellini A: Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti-proliferative activity on a breast-cancer cell line. Int J Cancer 1999;81:411-416.
30. Fraser JRE, Appelgren LE, Laurent TC: Tissue uptake of circulating hyaluronic acid. A whole body autoradiographic study. Cell Tissue Res 1983;233:285-293.
31. Moehler M, Gutzler F, Steinmann S, Boehme M, Raeth U, Stremmel W, Galle PR, Rudi J: Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. Chemotherapy 2003;49:85-89.
32. Uthman I, Raynauld JP, Haraoui B: Intra-articular therapy in osteoarthritis. Postgrad Med J 2003 934:449-453.
33. Koster R, Stilma JS: Healon as intravitreal substitute in retinal detachment surgery in 40 patients. Doc Ophthalmol 1986;64:13-17.
34. Kawcak CE, Frisbie DD, Trotter GW, McIlwraith CW, et al: Effects of intravenous administration of sodium hyaluronate on carpal joints in exercising horses after arthroscopic surgery and osteochondral fragmentation. Am J Vet Res 1997;58:1132-1140.
35. Erickson S, Fraser JRE, Laurent TC, Pertoft H, Smedsrod B: Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp Cell Res 1983;144:223-228.
36. Frebourg T, Lerebours G, Delpech B, et al: Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987;59:2104-2107.
37. Delpech B, Chevallier B, Reinhardt N, et al: Serum hyaluronan (hyaluronic acid) in breast cancer patients. Int J Cancer 1990;15:388-390.